Varenicline-Yuhan
Alternative Names: YHP-1903Latest Information Update: 28 Jan 2023
At a glance
- Originator Yuhan
- Class 3-ring heterocyclic compounds; Antivirals; Azabicyclo compounds; Benzazepines; Bridged-ring heterocyclic compounds; Eye disorder therapies; Pyrazines; Quinoxalines; Small molecules; Smoking cessation therapies
- Mechanism of Action Alpha4 beta2 nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Smoking withdrawal
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Smoking-withdrawal(In volunteers) in South Korea (PO, Tablet)
- 14 Jan 2020 Yuhan Corporation completes a phase I trial in Smoking withdrawal (In volunteers) in South Korea (PO) (NCT04225052)
- 19 Dec 2019 Phase-I clinical trials in Smoking withdrawal (In volunteers) in South Korea (PO) (NCT04225052)